2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 14th, 2025
Version: 2
Medical College of Wisconsin
cancer biology
biorxiv

CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization

Drouillard, D.Open in Google Scholar•Halyko, M.Open in Google Scholar•Cinquegrani, E.Open in Google Scholar•Poimenidou, M.Open in Google Scholar•Emosivbe, M.Open in Google Scholar•McAllister, D.Open in Google Scholar•Peterson, F. C.Open in Google Scholar•Marchese, A.Open in Google Scholar•Dwinell, M. B.Open in Google Scholar

Acute myeloid leukemia (AML) is a malignancy of immature myeloid blast cells with stem-like and chemoresistant cells being retained in the bone marrow through CXCL12-CXCR4 signaling. Current CXCR4 inhibitors that mobilize AML cells into the bloodstream have failed to improve patient survival, likely reflecting persistent chemokine receptor localization on target cells. Here we characterize the signaling properties of CXCL12-locked dimer (CXCL12-LD), a bioengineered variant of the naturally occurring oligomer of CXCL12. CXCL12-LD, in contrast to wild-type or locked monomer variants, was unable to induce chemotaxis in AML cells. CXCL12-LD binding to CXCR4 decreased G protein, [beta]-arrestin, and intracellular calcium mobilization signaling pathways, and indicated the locked dimer is a partial agonist of CXCR4. Despite these partial agonist properties, CXCL12-LD increased CXCR4 internalization compared to wildtype and monomeric CXCL12. Analysis of a previously published AML transcriptomic data showed CXCR4 positive AML cells co-express genes involved in survival, proliferation, and maintenance of a blast-like state. The CXCL12-LD partial agonist effectively mobilized stem cells into the bloodstream in mice suggesting a potential role for their use in targeting CXCR4. Together, our results suggest that enhanced internalization by CXCL12-LD partial agonist can avoid pharmacodynamic tolerance and may identify new avenues to better target G protein coupled receptors.

Similar Papers

biorxiv
Tue Apr 15 2025
Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells.
Patients with Acute Myeloid Leukemia (AML) subtypes, acute erythroleukemia and acute megakaryocytic leukemia (M6 and M7 AMLs, respectively) have a median survival of only a few months with no targeted effective treatment. Our gene expression analysis using the Cancer Cell Line Encyclopedia and CRISPR screen from DepMap showed that M6/M7 AMLs have high levels of the transcription factor GATA1 and d...
Raza, Y.
•
Elmasry, M.
•
Yu, G.
•
Chiappone, S. B.
...•
Luberto, C.
biorxiv
Tue Apr 15 2025
The carnosinase dipeptidase CNDP1 is a novel metabolic vulnerability in brain metastasis
Brain metastatic cells undergo metabolic adaptations, such as increased reliance on oxidative phosphorylation. Integrating proteomic and transcriptomic profiling of patient samples revealed a consistent upregulation of the carnosine dipeptidase-1 (CNDP1) in brain versus extracranial metastases. Carnosine is an abundant metabolite in brain and muscle, known to exert anti-proliferative effects on ca...
Gomez-Munoz, M. A.
•
Karz, A.
•
Navarro, M.
•
Osorio-Vasquez, V. M.
...•
Hernando, E.
biorxiv
Tue Apr 15 2025
Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models
Background Diffuse midline glioma (DMG) is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. Since MAPK pathway activation is upstream of cell proliferation, we hypothesized that MEK inhibitors may increase the anti-tumor effects of CDK4/6 inhibitors. Here, we evaluated the efficacy...
Tomita, Y.
•
Link, G.
•
Ge, Y.
•
Gold, E. R. H.
...•
Becher, O. J.
biorxiv
Tue Apr 15 2025
Splice-switching ASOs targeting an Alu-derived exon in the AURKA 5'UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, driven by oncogenic KRAS mutations and dysregulated oncogenes, such as SRSF1, MYC, and AURKA. Although KRAS-targeted therapies are in development, resistance mechanisms underscore the need to identify alternative vulnerabilities. Here, we uncover an SRSF1-AURKA-MYC oncogenic circuit, wherein SRSF1 regulates AURKA 5\'UTR al...
Kral, A. J.
•
Jia, L.
•
Sim, G.
•
Wan, L.
•
Krainer, A. R.
biorxiv
Tue Apr 15 2025
A Dual-Action Liposome-Peptide Formulation Synergistically Counteracts A Gain-of-Function p53 Mutant
Objective. Inactivation of p53 tumor suppressor functions, often through missense mutations, is essential for carcinogenesis. A sub-class of such p53 missense mutations gains new functions, including drug resistance and enhanced proliferation, in addition to its loss of function. Among the most frequent gain-of-function p53 mutants, R273H occurs in tumors of many tissue origins and imparts aggress...
Ghosh Chaudhary, S.
•
Bhowmick, S.
•
Bhattacharya, S.
•
Roy, S.
•
Ali, N.
biorxiv
Tue Apr 15 2025
The E3 ligase HECTD4 regulates COX-2 dependent tumor progression and metastasis
E3 ubiquitin ligases mediating turnover of proteins engaged in cancer progression point to key regulatory nodes. To uncover modifiers of metastatic competency, we conducted an in vivo genome-wide CRISPR-inactivation screen using cultured breast circulating tumor cells, following intravascular seeding and lung colonization. We identified HECTD4, a previously uncharacterized gene encoding a conserve...
Vuille, J. A.
•
Tanriover, C.
•
Micalizzi, D. S.
•
Ebright, R. Y.
...•
Haber, D. A.
biorxiv
Tue Apr 15 2025
Quantifying replication stress in cancer without proliferation confounding
Replication stress (RS) is a major driver of genomic instability and cancer development, caused by impaired DNA replication that can lead to chromosomal instability (CIN). Although RS is mechanistically linked to CIN, its relationship with cellular proliferation is complex. Depending on the context, RS can either promote or suppress cell growth. Existing RS gene expression signatures overlook this...
Jungk, P.
•
Kschischo, M.
biorxiv
Tue Apr 15 2025
Proteomic Remodeling During Tumor Cell-Induced Platelet Aggregation Unveils Metastatic Drivers in Colorectal Cancer
Background: Colorectal cancer (CRC) is frequently associated with metastasis, resulting in high mortality rates. Platelets are known to play a crucial role in the metastatic cascade influencing tumor microenvironment remodeling, promoting cell transformation, facilitating metastatic niche formation, and shielding circulating tumor cells from immune surveillance. However, platelet proteomic alterat...
Sauer, T.
•
Gruner, C.
•
Kern, K.
•
Rackisch, A.
...•
Gemoll, T.
biorxiv
Tue Apr 15 2025
Tumoral CD24 tunes platelets binding and pro-metastatic functions
One of the earliest steps of breast cancer metastasis occurs when tumor cells (TCs) disseminate through the bloodstream. There, they interact with several blood components. Among them, platelet favor TC survival and metastatic spread. While the binding of platelet to TC is highly variable, its molecular controls and downstream consequences remain unidentified. Here, we first document that high CD2...
Mittelheisser, V.
•
Liboni, C.
•
Mouriaux, C.
•
Trivigno, S. M. G.
...•
GOETZ, J. G.
biorxiv
Tue Apr 15 2025
Brief Pulses of High-Level Fluid Shear Stress Enhance Metastatic Potential and Rapidly Alter the Metabolism of Cancer Cells.
Circulating tumor cells (CTCs) face challenges to their survival including mechanical and oxidative stresses. Recently, we identified a mechano-adaptive response to transient fluid shear stress (FSS) exposure that enables cancer cells to survive mechanical destruction in the circulation and found that it involves an increase in the activation of RhoA-actomyosin signaling [1]. Because RhoA is likel...
Pope, A. N.
•
Moose, D. L.
•
Hudson, G. O.
•
Weresh, H. R.
...•
Henry, M. D.